InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Discover the complete record of transactions filed by Frenkel Ran, Vice-Président Exécutif. Officer active across 1 companies, notably Karyopharm Therapeutics Inc.. In total, 4 disclosures have been recorded. Total volume traded: €65k. The latest transaction was disclosed on 28 February 2022 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations4 total
068,250 shares0
Common Stock
SEC:0001209191-22-014629:0·
€31,2162,929 shares@ €10.65770.018% mcap47.7% of flow
Common Stock
SEC:0001209191-22-011643:0·
€17,1411,991 shares@ €8.60920.0099% mcap26.2% of flow
Common Stock
SEC:0001209191-22-008128:0·
€17,1411,991 shares@ €8.60920.0099% mcap100.0% of flow
Common Stock
SEC:0001209191-22-008128·
4 of 4 declarations
About Frenkel Ran
Ran Frenkel is the Executive Vice President and Chief Development Officer at Karyopharm Therapeutics Inc. He is responsible for strategic development and innovation within the company. His role is essential in positioning Karyopharm as a leader in the biopharmaceutical sector.
